TRDA Entrada Therapeutics, Inc.: institutional ownership and insider trading
135 funds reported holding $259M of Entrada Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $26.4M, with 26 new positions and 16 funds selling out; over the last 12 months insiders bought $1.64M and sold $15.1M on the open market; over its last four quarters it reported revenue of $4.69M and net income of −$166M.
TRDA revenue and earnings
- Quarter ended Jun 30, 2026: revenue $898K, net income −$42.8M, EPS -1.01
- Quarter ended Mar 31, 2026: revenue $875K, net income −$39.7M, EPS -0.95
- Quarter ended Dec 31, 2025: revenue $1.30M, net income −$39.2M, EPS -0.95
- Quarter ended Sep 30, 2025: revenue $1.61M, net income −$44.1M, EPS -1.06
Famous investors holding TRDA
- Izzy Englander (Millennium Management): $5.62M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $2.90M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.41M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $342K, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $238K, 0.0% of the portfolio
Largest institutional holders of TRDA
- BAKER BROS. ADVISORS LP — $37.3M
- 5AM Venture Management, LLC — $29.9M
- MPM ASSET MANAGEMENT LLC — $25.4M
- BlackRock, Inc. (BLK) — $19.0M
- VANGUARD GROUP INC — $16.8M
- Merck & Co., Inc. (MRK) — $12.8M
- VANGUARD CAPITAL MANAGEMENT LLC — $9.34M
- MPM BioImpact LLC — $9.22M
- TCG Crossover Management, LLC — $7.80M
- WELLINGTON MANAGEMENT GROUP LLP — $7.02M
Recent TRDA insider trades
- Sep 9, 2026: Gadicke Ansbert sold 259,837 shares ($1.91M)
- Sep 9, 2026: Mpm Bioventures 2018, L.P. sold 259,837 shares ($1.91M)
- Sep 3, 2026: Gadicke Ansbert sold 86,482 shares ($617K)
- Sep 3, 2026: Mpm Bioventures 2018, L.P. sold 86,482 shares ($617K)
5%+ owners
- ANSBERT GADICKE: 9.9% (Schedule 13D/A, filed Sep 10, 2026)